Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Vaccinex reports new biomarker research and plans for Phase 2 randomized clinical trial of pepinemab in Alzheimer's Disease at the AAIC in July
-
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026 Lausanne, Switzerland, July 7, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical...
-
– Comes just weeks after Firefly confirmed its active public-private partnership with the U.S. Department of War – KENMORE, N.Y, June 02, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc....
-
Polarean highlights 20+ ATS 2026 presentations advancing Xenon MRI as a biomarker platform for trials, treatment response, and pediatric lung disease.
-
Yatiri Bio is a precision medicine company focused on identifying and validating biomarkers that predict therapeutic response in oncology.
-
ORLANDO, Fla., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Codetta Bio™, a leader in multi-omic solutions that combine ultrasensitive protein quantification with simultaneous RNA and DNA analysis, today...
-
BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3...
-
PRESS RELEASE AB SCIENCE ANNOUNCES THE IDENTIFICATION OF A PLASMA BIOMARKER THAT INDICATES THE ACTIVITY OF MASITINIB IN TREATING AMYOTROPHIC LATERAL SCLEROSIS, AND THAT IS CAPABLE OF IDENTIFYING...
-
COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE L'IDENTIFICATION D'UN BIOMARQUEUR PLASMATIQUE MARQUEUR DE L'ACTIVITÉ DU MASITINIB DANS LE TRAITEMENT DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE, ET CAPABLE...
-
DURHAM, N.C., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Codetta Bio™, a leading innovator in multi-omic solutions that integrate ultrasensitive protein quantitation with simultaneous analysis of nucleic...